Q2 Earnings Estimate for Arcus Biosciences Issued By Wedbush

Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Equities researchers at Wedbush decreased their Q2 2025 EPS estimates for Arcus Biosciences in a research report issued to clients and investors on Wednesday, May 7th. Wedbush analyst R. Driscoll now expects that the company will earn ($1.11) per share for the quarter, down from their previous estimate of ($1.01). Wedbush has a "Outperform" rating and a $33.00 price target on the stock. The consensus estimate for Arcus Biosciences' current full-year earnings is ($3.15) per share. Wedbush also issued estimates for Arcus Biosciences' Q3 2025 earnings at ($1.13) EPS, Q4 2025 earnings at ($1.15) EPS, FY2025 earnings at ($4.53) EPS, FY2026 earnings at ($4.32) EPS, FY2027 earnings at ($3.60) EPS, FY2028 earnings at ($0.52) EPS and FY2029 earnings at $3.37 EPS.

A number of other research analysts have also commented on the stock. HC Wainwright upgraded shares of Arcus Biosciences from a "neutral" rating to a "buy" rating and upped their price target for the company from $18.00 to $24.00 in a research note on Wednesday, February 26th. Bank of America cut their price objective on shares of Arcus Biosciences from $22.00 to $17.00 and set a "neutral" rating for the company in a research report on Wednesday, February 19th. Barclays reduced their target price on Arcus Biosciences from $29.00 to $14.00 and set an "overweight" rating on the stock in a report on Wednesday, April 23rd. The Goldman Sachs Group decreased their price target on shares of Arcus Biosciences from $15.00 to $13.00 and set a "neutral" rating on the stock in a report on Thursday, May 8th. Finally, Morgan Stanley lowered their target price on Arcus Biosciences from $24.00 to $22.00 and set an "overweight" rating for the company in a report on Friday. Two equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $25.67.

Arcus Biosciences Stock Performance

Arcus Biosciences stock traded down $0.14 during mid-day trading on Friday, hitting $8.66. 1,053,508 shares of the company's stock traded hands, compared to its average volume of 836,839. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.24 and a quick ratio of 5.24. The firm has a 50 day simple moving average of $8.38 and a two-hundred day simple moving average of $12.30. Arcus Biosciences has a fifty-two week low of $6.50 and a fifty-two week high of $18.98. The stock has a market cap of $916.96 million, a price-to-earnings ratio of -2.75 and a beta of 0.88.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($1.14) EPS for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.12). The firm had revenue of $28.00 million during the quarter, compared to analyst estimates of $38.61 million. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. The business's revenue was down 80.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.05) EPS.

Institutional Trading of Arcus Biosciences

Institutional investors have recently made changes to their positions in the stock. R Squared Ltd bought a new stake in Arcus Biosciences during the 4th quarter valued at $26,000. E Fund Management Co. Ltd. purchased a new position in shares of Arcus Biosciences in the first quarter valued at about $82,000. Lazard Asset Management LLC boosted its holdings in shares of Arcus Biosciences by 3,321.3% during the fourth quarter. Lazard Asset Management LLC now owns 6,261 shares of the company's stock worth $93,000 after purchasing an additional 6,078 shares during the period. Knott David M Jr purchased a new position in Arcus Biosciences during the 1st quarter valued at about $94,000. Finally, US Bancorp DE grew its position in shares of Arcus Biosciences by 2,432.0% in the 4th quarter. US Bancorp DE now owns 6,887 shares of the company's stock worth $103,000 after buying an additional 6,615 shares during the last quarter. Hedge funds and other institutional investors own 92.89% of the company's stock.

Insider Transactions at Arcus Biosciences

In other Arcus Biosciences news, Director Yasunori Kaneko purchased 20,000 shares of the firm's stock in a transaction on Thursday, February 27th. The shares were purchased at an average cost of $10.06 per share, with a total value of $201,200.00. Following the completion of the purchase, the director now owns 28,400 shares of the company's stock, valued at $285,704. The trade was a 238.10% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Terry J. Rosen acquired 19,800 shares of the firm's stock in a transaction dated Thursday, February 27th. The stock was bought at an average price of $10.18 per share, for a total transaction of $201,564.00. Following the acquisition, the chief executive officer now owns 2,554,160 shares of the company's stock, valued at approximately $26,001,348.80. This trade represents a 0.78% increase in their position. The disclosure for this purchase can be found here. Insiders own 12.30% of the company's stock.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.